Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2001-03-02
2004-02-03
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S204100, C435S091330, C435S235100, C435S236000
Reexamination Certificate
active
06685948
ABSTRACT:
BACKGROUND OF THE INVENTION
Dengue (DEN) viruses belong to the genus flavivirus, within the family Flaviviridae. There are at least 70 flavivirus species, among which the most important human pathogens are the DEN viruses, yellow fever virus, and the Japanese (JE) and tick-borne encephalitis viruses. Diseases caused by the 4 serotypes of DEN virus (DEN1-4), dengue fever (DF) or dengue hemorrhagic fever/shock syndrome (DHF/DSS), are endemic or epidemic in tropical and sub-tropical countries around the world.
In a manner similar to that of yellow fever, dengue is transmitted between humans by the domestic mosquito vector,
Aedes aegypti
. Evidence has emerged for the existence of a sylvan cycle of transmission analogous to that of yellow fever, involving monkeys and several sylvatic Aedes species. Transovarial transmission has been demonstrated experimentally in these forest mosquito species.
In light of this evidence, a model of dengue fever transmission where the virus emerges from the jungle to infect urban populations may be suggested. In this model, monkeys serve as a reservoir for the virus and transmission of the virus from monkey to monkey occurs through a mosquito vector. According to this model, the virus is transmitted from mosquito to human and then from that infected human to other mosquitoes of the species
Aedes aegypti
. Once these mosquitoes are infected, the dengue virus is transmitted to other human hosts. These infected individuals then pass the dengue virus on to other
Aedes aegypti
mosquitoes and expand the range of infection. Person-to-person spread of dengue virus infection and disease does not occur.
At present, because of several demanding technical problems, there is no vaccine available to prevent the diseases caused by dengue virus infection (DF and DHF/DSS). For example, a suitable live virus vaccine ought not to replicate efficiently in the mosquito vector, since it is conceivable that a live, attenuated vaccine could revert to full virulence during replication in a mosquito that has fed on a vaccinee. Thus, a local or regional immunization program could lead to the spread of illness rather than the diminution of disease incidence in the vaccinated population. Accordingly, a safe and effective dengue virus vaccine will have a severely limited ability to be transmitted from human host to mosquito vector. The present invention seeks to provide such a vaccine and solve the long felt need for safe and effective vaccines directed to the known serotypes of dengue as well as to provide vaccines for other flaviviruses.
SUMMARY OF THE INVENTION
The flavivirus genome is a positive-stranded
~
11-kb RNA including 5′- and 3′-noncoding regions (NCR) of approximately 100 and 400 to 600 nucleotides, respectively. The 3′-NCR contains adjacent, thermodynamically stable, conserved short and long stem and loop structures (the 3′-SL), formed by the 3′-terminal
~
100 nucleotides. The nucleotide sequences within the 3′-SL are not well conserved among species. The requirement for the 3′-SL for replication was examined in the context of dengue virus, type 2, (DEN2) replication, by mutagenesis of an infectious cDNA copy of a DEN2 genome. Genomic full-length RNA was transcribed in vitro and used to transfect monkey kidney cells. A substitution mutation, in which the 3′-terminal 93 nucleotides comprising the wild type DEN2 3′-SL sequence were replaced by the 96 nucleotide sequence of the West Nile virus (WN) 3′-SL, was sublethal for virus replication. Analysis of the growth phenotypes of additional mutant viruses derived from RNAs containing DEN2-WN chimeric 3′-SL structures suggested that the wild type DEN2 nucleotide sequence forming the bottom half of the long stem and loop in the 3′-SL was required for viability. One 7 base pair substitution mutation in this domain resulted in a mutant virus that grew well in monkey kidney cells but was severely restricted in cultured mosquito cells. In contrast, transpositions and/or substitutions of the wild type DEN2 nucleotide sequence in the top half of the long stem and in the short stem and loop were relatively well tolerated, provided the stem-loop secondary structure was conserved. A mutant dengue virus that was observed to be replication-defective in mosquito cells in tissue culture was also shown to be replication-defective in adult mosquitoes. The methods discussed herein also contemplate utility for use against any flavivirus, since the 3′-SL structure is conserved among all the more than 20 flavivirus genomes that have been subjected to nucleotide sequence analysis to date.
REFERENCES:
patent: WO 93/06214 (1993-04-01), None
Chambers et al. Annual Review of Microbiology. 1990; 44: 649-88.*
Zeng et al. Journal of Virology. Sep. 1998; 72 (9): 7510-7522.*
Markoff et al. Journal of Virology. 2002; 76 (7): 3318-3328.*
Grange, T., et al. (1985) Stable secondary structures at 3′-end of the genome of yellow fever virus (17 D vaccine strain). FEBS Lett. 188(1):159-163.
Irie, K., et al. (1989) Sequence analysis of cloned dengue virus type 2 genome (New Guinea C strain). Gene 75:197-211.
Jacobson, S. J., et al. (1993) Biochemical and genetic evidence for a pseudoknot structure at the 3′ terminus of the poliovirus RNA genome and its role in viral RNA amplification. J. Virol. 67(6):2961-2971.
Kuhn, R. J et al. (1992) Attenuation of Sindbis virus neurovirulence by using defined mutations in nontranslated regions of the genome RNA. J. Virol. 66(12):7121-7127.
Li, W., et al. (1996) Effect of West Nile virus (WNV) 5′ and 3′ regions on translation. Abstracts of the American Society for Virology 15th Annual Meeting., Abstr. W2-1, p. 85.
Men, R., et al. (1996) Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J. Virol. 70(6):3930-3937.
Mohan, P. M., et al. (1991) Detection of stable secondary structure at the 3′ terminus of dengue virus type 2 RNA. Gene 108:185-191.
Monath, T. P. (1994) Dengue: the risk to developed and developing countries. Proc. Natl. Acad. Sci. USA 91:2395-2400.
Pogue, G. P., et al. (1996) Autoantigens interact with cis-acting elements of rubella virus RNA. J. Virol. 70(9):6269-6277.
Polo, S., et al. (1997) Infectious RNA transcripts from full-length dengue virus type 2 cDNA clones made in yeast. J. Virol. 71(7):5366-5374.
Rice, C. M., et al. (1985) Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 229:726-733.
Schägger, H., et al. (1987) Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in range from 1 to 100 kDa. Anal. Biochem. 166:368-379.
Sherman, F. (1991) Getting started with yeast. Methods Enzymol. 194:3-21.
Shi, P.-Y., et al. (1996) Evidence for the existence of a pseudoknot structure at the 3′ terminus of the flavivirus genomic RNA. Biochemistry 35:4222-4230.
Shi, P.-Y., et al. (1996) Cell proteins bind specifically to West Nile virus minus-strand 3′ stem-loop RNA. J. Virol. 70(9):6278-6287.
Spencer, F., et al. (1993) Targeted recombination-based cloning and manipulation of large DNA segments in yeast. Methods: Companion to Methods Enzymol. 5:161-175.
Stern, S., et al. (1986) Location of the binding site for protein S4 on 16 S Ribosomal RNA by chemical and enzymatic probing and primer extension. J. Mol. Biol. 192:101-110.
Stollar, V., et al. (1967) Studies of the nature of dengue viruses. III. RNA synthesis in cells infected with type 2 dengue virus. Virology 33:650-658.
Takegami, T., et al. (1986) Nucleotide sequence at the 3′ end of Japanese encephalitis virus genomic RNA. Virology 152:483-486.
Tan, B.-H., et al. (1996) Recombinant denque type 1 virus NS5 protein expressed inEscherichia coliRNA-dependent RNA polymerase activity. Virology 216:317-325.
Valle, R. P. C., et al. (1993) Elimination of L-A double-stranded RNA
Markoff Lewis
Zeng Lingling
Foley Shanon
Housel James
Knobbe Martens Olson & Bear LLP
The United States of America as represented by the Department of
LandOfFree
Replication-defective dengue viruses that are... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Replication-defective dengue viruses that are..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Replication-defective dengue viruses that are... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3339296